Description

Alluvi™ Retatrutide is an advanced investigational injectable therapy targeting GLP-1, GIP, and glucagon receptors for a triple-action approach to weight loss, glucose control, and metabolic health. Developed as part of next-generation incretin-based therapeutics, Retatrutide has shown superior efficacy in early clinical trials compared to semaglutide and tirzepatide.

Key Benefits:

• Triple receptor agonist for enhanced appetite suppression and calorie control.
• Significant weight loss potential (up to 24% average body weight reduction in studies).
• Improves glycemic control and insulin sensitivity.
• Potential cardiovascular and liver health benefits.
• Once-weekly subcutaneous injection.

Clinical Indications:

• Obesity management (BMI ≥30)
• Overweight patients with comorbidities (BMI ≥27)
• Adjunct to diet and exercise for type 2 diabetes (pending approval)

Dosage & Administration:

• Standard dosing: Once weekly subcutaneous injection.
• Starting dose and titration schedule determined by healthcare provider.
• Supplied in prefilled pen format (varied mg strengths available).